RSS Feeds
Search

Press releases

Press releases

Displaying 1..10 of 17 - per page Next page
Order by
GenOdyssee S.A. announced today that the Journal of antimicrobial Agents and Chemotherapy (AAC*), has accepted a manuscript describing stronger and more sustained inhibitory effect of GenOdyssee's lead antiviral drug candidate, GEA007.1 More
New summary from Partneringdesk highlights trends in dealmaking from the top pharma and biotech companies More
A dozen University of Western Ontario research projects, including ensuring innovative research on Metabolic Syndrome and personalized medicine, have received $19-million from the Ontario Research Fund. More
STOCKHOLM, SWEDEN—Her Majesty the Queen of Sweden will officially open the Salk Institute's annual International Council meeting at the Grand Hotel in Stockholm. More
MR Hannaman MD has been invited to speak at two pharmaceutical conferences with information related to new biogenic animal models of pain. More
Data describing the higher antiviral potency of GenOdyssee's lead antiviral IFN alpha variant GEA007.1 compared to IFN alpha 2b, against HCV replication, will be presented in Paris, at the International Symposium on Viral Hepatitis and Liver Disease More
RidePharm announced today that it will license out the human monoclonal Fab inhibiting intracellular HCV replication More
Combined Company to Lead in Development and Commercialization of Neuroscience Compounds More
Gene Bridges granted exclusive patent for Red®/ET® Recombination More
Displaying 1..10 of 17 - per page Next page
Order by

Related Reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us